Ziemann U, Bruns D, Paulus W
Department of Clinical Neurophysiology, University of Göttingen, Germany.
Neurosci Lett. 1996 Apr 26;208(3):187-90. doi: 10.1016/0304-3940(96)12575-1.
Focal transcranial magnetic stimulation was used to evaluate the effect a single oral dose (0.125 mg) of the dopamine agonist pergolide on the excitability of the motor cortex in five healthy subjects. Resting and active motor thresholds of the abductor digiti minimi muscle were unaffected. The mean duration of the cortical silent period was significantly lengthened by up to 22 ms. The cortico-cortical inhibition as studied by a paired conditioning-test stimulation (interstimulus intervals of 1-5 ms) was enhanced significantly while the cortico-cortical facilitation at longer intervals (6-15 ms) showed only an insignificant trend towards less facilitation. All effects peaked at 3 h after drug intake and were reversible after 24 h. Peripheral motor excitability as tested by the duration of the peripheral silent period and the size of the maximum M wave remained unchanged. The present data support the view that pergolide is capable of enhancing motor cortex inhibition which is known to be deficient in idiopathic Parkinson's disease.
采用局灶性经颅磁刺激评估单剂量口服多巴胺激动剂培高利特（0.125毫克）对5名健康受试者运动皮质兴奋性的影响。小指展肌的静息和主动运动阈值未受影响。皮质静息期的平均时长显著延长，最长可达22毫秒。通过配对条件-测试刺激（刺激间隔为1 - 5毫秒）研究的皮质-皮质抑制作用显著增强，而较长间隔（6 - 15毫秒）的皮质-皮质易化作用仅显示出不显著的减弱趋势。所有效应在服药后3小时达到峰值，24小时后可逆。通过外周静息期时长和最大M波大小测试的外周运动兴奋性保持不变。目前的数据支持这样一种观点，即培高利特能够增强运动皮质抑制作用，而这种抑制作用在特发性帕金森病中已知是不足的。
